Please refer attachment
Awaiting price reaction for this filing.
Piramal Pharma reported FY25 consolidated revenue of ₹9,151 Cr, up 12% YoY, crossing the $1Bn revenue mark. EBITDA grew 15% to ₹1,580 Cr with margins steady at 17%, while profit after tax surged over 5x to ₹91 Cr (vs ₹18 Cr in FY24). All three segments grew: CDMO up 15% to ₹5,447 Cr led by on-patent commercial manufacturing (up 50%+ YoY to $179mn), CHG up 8% to ₹2,633 Cr, and India Consumer Healthcare up 11% to ₹1,093 Cr, crossing the ₹1,000 Cr milestone. Net Debt/EBITDA improved significantly to 2.7x from 5.6x in FY23. Management reaffirmed FY2030 aspirations of $2Bn revenue, 25% EBITDA margins, high teens ROCE, and ~1x Net Debt/EBITDA, supported by innovation-led CDMO growth, Sevoflurane capacity expansion, and power brand momentum in consumer healthcare.
Positive for shareholders — broad-based revenue growth, margin stability, sharp deleveraging, and clear long-term targets suggest improving fundamentals. Near-term CHG margin softness due to capacity expansion costs is expected to reverse from FY26, while the on-patent CDMO pipeline offers strong visibility for future growth.